Use of imatinib mesylate in elderly patients in Northern Ireland: Evidence of comparable haematological and molecular responses to younger patients

Hematology

Volumn 13, Issue 3, 2008, Pages 133-136

  Sheehy, O M ^a   Irvine, A E ^a,b   Cuthbert, R J G ^a   Humphreys, M W ^a   McMullin, M F ^a,b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Chronic myeloid leukaemia (CML); Elderly; Imatinib; Prognosis

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NORTHERN IRELAND; PIPERAZINES; PROGNOSIS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 55849109626     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X316004     Document Type: Article

References (14)

1. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
2. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858
3. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
4. Menzin J, Lang K, Earle CC, Glendenning A. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: A population-based analysis. Drugs Aging 2004; 21: 737-746
5. Cortes J, Talpaz M, O'Brien S et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98: 1105-1113.
6. Latagliata R, Breccia M, Carmosino I et al. Elderly patients with Phz chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment. Erratum appears in Leuk Res 2005; 29(9): 1099
7. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
8. Colombat M, Fort MP, Chollet C et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006; 91: 162-168.
9. Rosti G, Iacobucci I, Bassi S, Castagnetti F et al. Impact of age on the outcome of patients with chronic myeloid leukaemia in late chronic phase: Results of a phase II study of the GIMEMA CML working party. Haematologica 2007; 92; 101-105.
10. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49-61.
11. Gabert J, Beillard E, van der Velden VH et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
12. McCallum L, Price S, Planque N et al. A novel mechanism for BCR-ABL action: Stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 2006; 108: 1716-1723
13. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996; 100: 452-455.
14. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006; 20: 29-41.